GO
Loading...

Amgen Inc

More

  • Midday Glance: Biotechnology companies Monday, 15 Dec 2014 | 1:43 PM ET

    Amgen Inc. fell $3.39 or 2.1 percent, to $161.14. Biogen Idec fell $5.90 or 1.7 percent, to $338.59. Celgene Corp. fell $1.30 or 1.1 percent, to $113.19.

  • Early Glance: Biotechnology companies Monday, 15 Dec 2014 | 12:00 PM ET

    Amgen Inc. fell $1.94 or 1.2 percent, to $162.60. Biogen Idec fell$. 44 or. 1 percent, to $344.05. Celgene Corp. rose$. 47 or. 4 percent, to $114.96.

  • Final Glance: Biotechnology companies Friday, 12 Dec 2014 | 6:03 PM ET

    Amgen Inc. fell $1.55 or. 9 percent, to $164.53. Biogen Idec rose $2.16 or. 6 percent, to $344.49. Celgene Corp. fell $2.25 or 1.9 percent, to $114.49.

  • Midday Glance: Biotechnology companies Friday, 12 Dec 2014 | 1:18 PM ET

    Amgen Inc. rose$. 25 or. 1 percent, to $166.33. Biogen Idec rose $1.12 or. 3 percent, to $343.45. Celgene Corp. fell$. 99 or. 8 percent, to $115.75.

  • Early Glance: Biotechnology companies Friday, 12 Dec 2014 | 10:31 AM ET

    Amgen Inc. rose$. 24 or. 1 percent, to $166.32. Biogen Idec rose $3.18 or. 9 percent, to $345.51. Celgene Corp. fell$. 17 or. 1 percent, to $116.57.

  • ZURICH, Dec 12- Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson& Johnson's Stelara. The data follows results last year showing Cosentyx, also known as secukinumab, was superior to Amgen's Embrel in a head-to-head study. Other drugmakers working on new...

  • Final Glance: Biotechnology companies Thursday, 11 Dec 2014 | 6:02 PM ET

    Amgen Inc. rose$. 69 or. 4 percent, to $166.08. Biogen Idec fell $1.26 or. 4 percent, to $342.33. Celgene Corp. rose $1.10 or 1.0 percent, to $116.74.

  • Midday Glance: Biotechnology companies Thursday, 11 Dec 2014 | 1:18 PM ET

    Amgen Inc. rose $2.69 or 1.6 percent, to $168.08. Biogen Idec rose $3.88 or 1.1 percent, to $347.47. Celgene Corp. rose $2.16 or 1.9 percent, to $117.80.

  • Early Glance: Biotechnology companies Thursday, 11 Dec 2014 | 11:28 AM ET

    Amgen Inc. rose $2.53 or 1.5 percent, to $167.92. Biogen Idec rose $2.90 or. 8 percent, to $346.49. Celgene Corp. rose $1.91 or 1.7 percent, to $117.55.

  • CHICAGO, Dec 10- Small startup NextCode Health will use gene-hunting tools pioneered by Iceland's Decode Genetics to help a leading U.S. pediatric hospital identify causes of rare diseases in children, marking the latest foray of genetic sequencing into routine medical practice. Cambridge, Massachusetts- based NextCode, a Decode spin-off, has signed a deal...

  • Final Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 6:09 PM ET

    Amgen Inc. fell $4.00 or 2.4 percent, to $165.39. Biogen Idec fell $4.02 or 1.2 percent, to $343.59. Celgene Corp. fell $3.04 or 2.6 percent, to $115.64.

  • Midday Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 1:18 PM ET

    Amgen Inc. fell $1.19 or. 7 percent, to $168.20. Biogen Idec fell $1.82 or. 5 percent, to $345.79. Celgene Corp. fell$. 97 or. 8 percent, to $117.71.

  • Early Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 10:41 AM ET

    Amgen Inc. rose$. 07 or percent, to $169.46. Biogen Idec fell$. 17 or percent, to $347.44. Celgene Corp. fell$. 39 or. 3 percent, to $118.29.

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • Final Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 6:10 PM ET

    Amgen Inc. fell $2.25 or 1.3 percent, to $169.39. Biogen Idec rose $3.56 or 1.0 percent, to $347.61. Celgene Corp. rose$. 49 or. 4 percent, to $118.68.

  • Midday Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 1:21 PM ET

    Amgen Inc. fell $2.16 or 1.3 percent, to $169.48. Biogen Idec fell$. 23 or. 1 percent, to $343.82. Celgene Corp. rose$. 35 or. 3 percent, to $118.54.

  • Early Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 10:21 AM ET

    Amgen Inc. fell $2.53 or 1.5 percent, to $169.11. Biogen Idec fell $2.51 or. 7 percent, to $341.54. Celgene Corp. fell $1.02 or. 9 percent, to $117.17.

  • Sandoz loses bid to shield psoriasis drug Friday, 5 Dec 2014 | 2:09 PM ET

    Dec 5- The top U.S. patent appeals court has upheld the dismissal of a lawsuit brought by Sandoz Inc that sought to shield its planned version of Amgen Inc's psoriasis and arthritis drug Enbrel from patent lawsuits. Taranto only ruled that the lawsuit against Amgen was premature because Sandoz had not yet sought approval for the drug from the U.S. Food and Drug...

  • Dec 3- U.S. health regulators on Wednesday approved an Amgen Inc drug that helps the immune system fight a rare type of leukemia, more than five months ahead of the expected decision date. Anthony Stein, professor of hematology at City of Hope outside Los Angeles who worked on clinical trials of blinatumomab, called the approval "very important" for patients.

  • Cramer's heated love affair with biotech Tuesday, 2 Dec 2014 | 6:33 PM ET
    File photo: Michael LeClair, left, and Kevin Fleurimond, in the manufacturing room of Biogen Idec.

    As the global economy faces headwinds each day, Jim Cramer knows this group can withstand stormy weather more often than the rest.